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ABSTRACT
Objective. To determine the clinical 
characteristics of simultaneous occur-
rence of antitopoisomerase (ATA) and 
anticentromere (ACA) autoantibodies 
in systemic sclerosis (SSc). 
Methods. Data of patients (n=4,687) 
fulfilling the ACR criteria for SSc and 
followed in the EULAR Scleroderma 
Trials and Research (EUSTAR) cohort 
were analysed. Sera from patients with 
simultaneous ATA and ACA were rean-
alysed centrally by indirect immunoflu-
orescence, enzyme immunoassay, and 
immunoblot to confirm antibody status. 
Results. A total of 29 patients (0.6%) 
had been documented double-positive 
for both ATA and ACA in the EUS-
TAR database. Sera of 14 cases were 
available for central analysis, of which 
8 were confirmed to unequivocally 
contain both antibodies. The double-
positive patients were on average 52.4 
years of age, 87.5% were female, and 
62.5% had diffuse cutaneous (dc) SSc. 
Compared with matched ACA single-
positive disease, cutaneous and vis-
ceral complications were more preva-
lent in double-positive cases, but this 
prevalence did not differ significantly 
in comparison to ATA single-positives.
Conclusions. Coexistence of ATA and 
ACA can be found at low prevalence 
in SSc. The clinical features of double-
positive patients are not clearly dis-
similar to those of patients harbouring 
only ATA. The data do not support a 
direct involvement of these antibodies 
in the pathogenesis of established SSc, 
but may lack statistical power.
Introduction
Systemic sclerosis (SSc) is an uncom-
mon multisystem connective tissue 
disease characterised by microvascular 
damage and extensive fibrosis of the 
skin as well as internal organs (1). In ad-
dition, immunological abnormalities are 
typically observed in patients with SSc, 
the most prominent being the presence 
of circulating serum autoantibodies di-
rected against specific nuclear compo-
nents. In more than 90% of the patients 
with SSc, antinuclear antibodies (ANA) 
predominantly reacting with topoi-
somerase I, centromere proteins, RNA 
polymerases, or Th/To are detectable 
(2, 3). These antibodies are considered 
highly specific for SSc and their pres-
ence is associated with distinct clinical 
manifestations, organ involvement, and 
risk of mortality (3, 4). Furthermore, 
SSc-specific autoantibodies represent 
risk markers that predict progression 
from isolated Raynaud’s phenomenon to 
definite SSc (5).
The first and hence best documented 
antibody specificities in SSc are an-
ticentromere (ACA) and antitopoi-
somerase I (ATA) antibodies. ACA and 
ATA have been routinely measured in 
clinical laboratories for many years, 
and numerous detection systems are 
nowadays commercially available (6, 
7). In general, ACA and ATA occur in 
~60% of SSc patients worldwide, but 
the reported range (40 to 90%) is very 
wide (1-3). Genetic variations, clas-
sification criteria for SSc, and choice 
of antibody detection methods may all 
have contributed to the differences in 
the reported antibody frequencies (8-
10). Interestingly, ACA and ATA are 
virtually always mutually exclusive (2, 
3, 8-10).
The prevalence of clinical disease fea-
tures and laboratory abnormalities in 
SSc was recently assessed in a large, 
multinational SSc cohort, organised by 
the EULAR Scleroderma Trials and 
Research (EUSTAR) group (11). Pa-
tients evaluated in this database fulfil 
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the American College of Rheumatol-
ogy (ACR) classification criteria of 
SSc (12). About one-third of EUSTAR 
patients were positive for ATA and an-
other third was positive for ACA. The 
majority of patients with ATA suffered 
from the diffuse form of cutaneous 
scleroderma (dcSSc), whereas ACA oc-
curred mostly in patients with limited 
cutaneous SSc (lcSSc). There was a sig-
nificantly shorter lag period between the 
onset of Raynaud’s phenomenon and the 
first non-Raynaud’s clinical feature of 
disease in EUSTAR patients with ATA, 
as compared to ACA positive patients. 
On multivariate analysis, autoantibody 
status was found to be independently 
associated with the prevalence of organ 
manifestations. For example, the pres-
ence of ATA was the strongest predictor 
of complications by pulmonary fibrosis 
and digital ulcers, whereas the absence 
of ACA strongly predicted the presence 
of synovitis, joint contractures, and pul-
monary fibrosis (11). The predictive 
value of ATA and ACA, thus, raises the 
possibility that these autoantibodies are 
directly or indirectly involved in the 
pathogenesis of SSc. Likewise, it may 
also be suggested that distinct and inde-
pendent pathogenic mechanisms associ-
ated with these well-defined antibodies 
are involved in SSc.
Although individuals are generally 
positive for either ATA or ACA, the 
concomitant existence of ATA and 
ACA in a single patient with SSc has 
occasionally been reported in the liter-
ature (13-16). The clinical and labora-
tory characteristics of these cases may 
contribute to our understanding of the 
pathogenic role of ATA and ACA in 
SSc. However, the exceptionally rare 
prevalence of cases expressing both 
autoantibodies has hampered such 
evaluation. The objective of this study 
was to take advantage of the large EU-
STAR database and to identify multiple 
SSc patients with coincident ATA and 
ACA, allowing a meaningful compari-
son of the clinical features of patients 
harbouring both antibody specificities 
(‘double-positives’) with those of pa-
tients having only one specificity (‘sin-
gle-positives’).
In a first step, the EUSTAR database 
was assessed for patients who were 
registered as being positive for both 
ATA and ACA. Second, in order to cir-
cumvent the problem of the variety in 
antibody detection methods used at the 
different participating centres, serum 
samples of these patients were re-ana-
lysed centrally. Finally, clinical charac-
teristics of patients with SSc who were 
unequivocally positive for both ATA 
and ACA were compared to those of 
patients having only ATA or ACA. 
Materials and methods
The EUSTAR database 
and autoantibody status
The structure and organisation of the 
EUSTAR database have been described 
previously (11). For each individual 
SSc patient entered in the EUSTAR da-
tabase after informed written consent, 
a minimal essential data set (MEDS) is 
recorded that covers demographic data, 
disease duration, organ involvement, 
and basic laboratory data. The presence 
or absence of ANA, ACA, and ATA in 
a patient’s serum is documented in the 
MEDS via simple yes/no answers with 
positivity being defined as “above the 
cut-off value of the test employed by the 
examining laboratory”. 
Patient samples
This study focused on patients who 
were registered in the EUSTAR data-
base up to November 2007, fulfilled 
the ACR-criteria for SSc (12), and 
were documented by the respective 
centre as being positive for both ACA 
and ATA on at least one of their an-
nual visits. The unique patient numbers 
of these cases were identified and the 
corresponding EUSTAR centres were 
requested to confirm the autoantibody 
status and medical data documented in 
the MEDS. Centres were also asked for 
more detailed information, i.e. the anti-
body detection method used, the assay 
manufacturer, the cut-offs employed, 
and the original results obtained. In 
addition, centres were asked for avail-
ability of stored serum samples and 
requested to send an aliquot of the 
sera to the reference laboratory of this 
study (Medical Immunology, Univer-
sity Hospital Basel, Switzerland) for 
central re-analysis. All serum samples 
were stored at -80°C until testing.
Autoantibody measurement
ANA were determined by indirect im-
munofluorescence (IIF) using HEp-2 
cells (Inova Diagnostics, San Diego, 
CA) as substrate, and applying serial 
serum dilutions of 1:40 to 1:5120. Ti-
tres of 1:80 or more were regarded as 
positive. For each sample, the end-point 
titre and IIF staining pattern were in-
dependently recorded by three experi-
enced observers. A fine speckled nucle-
oplasmic and nucleolar staining pattern 
of interphase cells accompanied by a 
dense staining of the metaphase plate in 
mitotic cells was regarded indicative for 
ATA, whereas a pattern of discrete dots 
in interphase and metaphase nuclei was 
regarded as characteristic for ACA (17, 
18). This implies theoretically that the 
IIF pattern triggered by ATA may mask 
the ACA pattern when occurring in one 
sample. Therefore, in cases where the 
ATA-like pattern appeared dominant, 
the presence of concomitant ACA was 
evaluated by competitive inhibition as-
says. Briefly, serum samples were pre-
incubated with soluble topoisomerase I 
(10 ug/ml) for 1 hour at room tempera-
ture using a 1:1 mixture of both native 
antigen purified from bovine thymus 
(Inova Diagnostics) and recombinant 
human topoisomerase I protein (Phadia, 
Freiburg, Germany) before being tested 
on HEp-2 slides.
In addition to the HEp-2 cell IIF analy-
ses, ATA and ACA were specifically 
detected and quantified by enzyme 
immunoassays (EIAs) and by line im-
munoblot assays (LIAs). These two 
methods currently represent widely 
used techniques for the detection of 
ATA and ACA in European clinical 
laboratory practice. For the EIAs, com-
mercial ELISA kits (Inova Diagnostics) 
and an automated fluorescence EIA 
(FEIA) system (EliA™; Phadia) were 
used. The centromere antigen used in 
both systems is recombinant CENP-B 
protein, but the ELISA additionally 
contains recombinant CENP-A. The 
topoisomerase I antigen is purified 
from bovine thymus in the ELISA for 
ATA detection, but is of recombinant 
origin in the FEIA. Assay procedures 
and cut-off values (20 U for ELISA, 
and 10 U/ml for FEIA) were followed 
exactly according to the instructions 
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of the respective manufacturer. For the 
LIAs, membrane strips coated with re-
combinant CENP-B and topoisomerase 
I (Euroimmun, Lübeck, Germany), or 
with recombinant CENP-B and na-
tive topoisomerase I (Innogenetics, 
Brussels, Belgium) were used. LIA 
were performed, evaluated and com-
pared with controls according to the 
manufacturer’s instructions. All serum 
samples were additionally tested for the 
presence of anti-RNA Polymerase III 
antibodies (ARA) by an ELISA assay 
(Inova Diagnostics), and for antibod-
ies against SS-A (SS-A60 and Ro52), 
SS-B, Sm (SmD), U1-RNP, and Jo-1 by 
FEIA (Phadia).
Data analyses
SSc presentations were analysed cross-
sectionally for differences in demo-
graphic and clinical features. For each 
patient the available data of the last 
visit was used. Group means and me-
dians were compared by t-tests and 
Wilcoxon Rank sum test, respectively. 
Group percentages were compared by 
chi-square or Fisher’s exact test. The 
dataset was analysed using Stata ver-
sion 11.0 (StataCorp Inc., College Sta-
tion, TX, US). Each double-positive 
case was compared with five gender- 
and centre-matched controls harbour-
ing either ACA or ATA alone.
Results
As of 31st of October 2007, a total of 
4,687 SSc patients from 168 centres 
in 25 European and 19 non-European 
countries met the study criteria. Al-
most all of these subjects were Cauca-
sian. A total of 1,681 (35.9%) patients 
were documented in the database as 
being positive for ATA, whereas 1,546 
(32.9%) patients were positive for 
ACA. A total of 1,500 (32.0%) patients 
were documented as being negative 
for both ATA and ACA. Finally, there 
were 29 (0.6%) patients who had been 
scored positive for both ATA and ACA 
by the respective investigator. All of 
the patients who were claimed to show 
positivity for both ATA and ACA were 
also scored positive for ANA. Serum 
samples from 14 of these patients were 
available for central analysis. The 15 
patients of whom no serum was avail-
able were excluded from the data analy-
sis. 
Coexistence of ATA and ACA 
in patients with SSc 
Of the 14 patients in whom both ACA 
and ATA had been detected by the doc-
umenting centre, sera from 8 patients 
gave an unequivocal positive result 
by both IIF and EIAs upon central re-
analysis. These 8 sera clearly showed a 
staining pattern by IIF on HEp-2 sub-
strate cells consistent with the presence 
of ATA (titers ranging from 1:160 to 
1:1280). Five of these 8 sera concomi-
tantly demonstrated the characteristic 
ANA pattern associated with ACA (ti-
ters ranging from 1:160 to 1:1280, Fig. 
1A-C). In the remaining 3 sera, the typ-
ical ACA pattern became only visible 
in the IIF assay after inhibition of ATA 
Fig. 1. ANA patterns revealed by IIF using HEp-2 substrate cells. (A) Serum from a SSc patient positive for ACA revealing a typical pattern of discrete 
dots in interphase and metaphase. (B) A patient with ATA demonstrating the characteristic fine speckled nucleoplasmic and nucleolar staining pattern of 
interphase cells accompanied by a dense staining of the metaphase plate in mitotic cells. (C) A combined ACA and ATA pattern observed with the serum of 
a patient double-positive for ACA and ATA. (D) A dominant ATA pattern masking the ACA pattern in the serum of a patient double-positive for high levels 
of ATA and relatively low levels of ACA. Note that the typical ACA pattern is not readily visible with this patient’s serum. (E) In the latter case, the ACA 
stain became only visible after preabsorption of the ATA.
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reactivity by preincubation of serum 
samples with the topoisomerase I an-
tigen (Fig. 1D-E). Interestingly, these 
sera had relatively low titers of ACA 
(range 1:80–1:320) and relatively high 
ATA titers (range 1:640 to 1:1280), 
indicating that ATA, when present in 
relatively high concentrations, masks 
the ACA staining pattern in IIF testing.
In serum samples of two patients, only 
ACA could be detected, but these sam-
ples were taken at different time points 
than the ones at which both ACA and 
ATA were observed by the respective 
centres. As ATA titers may change in 
time (19, 20), ATA could have theoreti-
cally been disappeared in these cases. 
However, because the coexistence of 
ACA and ATA could no longer be un-
equivocally confirmed, the two patients 
were excluded from subsequent data 
analysis.
The 4 remaining patients that were reg-
istered positive for both ACA and ATA 
in the EUSTAR database were classi-
fied as false positive for one of the two 
antibodies after central re-analysis. In 2 
of these 4 cases, ACA were unequivo-
cally detectable, but the sera did not 
have the typical ATA staining pattern 
by IIF, and did not show reactivity to 
topoisomerase I by the EIAs that em-
ploy recombinant protein (i.e. FEIA 
(Phadia) and LIA (Euroimmun)). How-
ever, the sera demonstrated positive re-
activity for topoisomerase I when EIAs 
were used that incorporate native anti-
gen purified from natural sources (i.e. 
ELISA (Inova) and LIA (Innogenet-
ics)). Interestingly, the clinical centres 
that had registered the serum samples 
of these two patients as ACA and ATA 
double-positive, reported having used 
such native topoisomerase I EIA for 
ATA detection. Based on these results 
the two cases were considered ACA, 
but not ATA positive and were excluded 
from this analysis. Likewise, one addi-
tional case was excluded, because its 
ATA positivity appeared to have been 
based on a borderline positive EIA re-
sult (i.e. 11 U/ml by EliA™ (Phadia); 
cut-off 10 U/ml) by the clinical cen-
tre. As expected, the presence of ATA 
could not be unequivocally confirmed 
upon re-analysis of the serum by any 
of the detection methods. Finally, one 
case was unequivocally ATA positive, 
but ACA could not be detected by any 
of the used methods. It is of interest to 
note that the serum of this patient did 
not have the classical ACA staining 
pattern by IIF, but produced a discrete 
speckled pattern on interphase HEp-2 
cells without concomitant staining of 
mitotic cells. We concluded that this 
staining pattern, also known as multi-
ple nuclear dots pattern (21), had mis-
takenly been interpreted by the centre 
as ACA pattern, and we excluded this 
case from further analysis. 
Prevalence of other nuclear 
autoantibodies in SSc patients 
with coexisting ATA and ACA
The presence of autoantibodies against 
SS-A/Ro, SS-B/La, SmD, U1-RNP, Jo-
1, and RNA polymerase III in the serum 
of all 8 SSc patients with coexisting 
ACA and ATA is detailed for each in-
dividual in Table I. Regarding the three 
major SSc-specific autoantibodies (1-
3), none of the patients who were posi-
tive for both ATA and ACA had detect-
able levels of ARA. Four patients posi-
tive for ACA and ATA were also posi-
tive for anti-SS-A/Ro antibodies. Sera 
of two of these patients reacted with the 
Ro52 antigen only, whereas serum of 
one patient showed antibodies against 
Ro60 only, and one patient had anti-
bodies to both SS-A/Ro antigens. No 
significant levels of antibodies against 
SS-B, Sm (SmD), U1-RNP, and Jo-1 
could be detected in any of the ATA and 
ACA double-positive patients.
Clinical associations of coexisting 
ATA and ACA in patients with SSc
Clinical and serological data from the 
last available EUSTAR visit of the eight 
SSc patients harbouring both serum 
antibodies are shown in Table I. The 
eight double-positive patients were on 
average 53.2 years of age at their last 
visit, similar to the ATA single-positive 
and ACA single-positive control sub-
jects (Table II). Most of them (87.5%) 
were female, as was the case -as a con-
sequence of gender matching- in the 
ACA and ATA single-positive control 
groups. The frequency of dcSSc in the 
ACA and ATA double-positive group 
(62.5%) was not significantly differ-
ent than the ATA single-positive con-
trols, but significantly higher than in 
the ACA single-positive control group. 
In the double-positive group, the 
Raynaud’s phenomenon had begun at a 
slightly but statistically not significant 
younger age than in the other groups, 
but the age at the first non-Raynaud’s 
feature of SSc and the time interval 
Table I. Clinical features of the eight SSc patients with coexisting ATA and ACA. The age at last follow-up is given in years. Lung fibrosis 
refers to any interstitial lung involvement seen on conventional chest x-ray. 
Patient Gender Age Age at Age at SSc Max Last Renal PH Lung DLCO Alive Other ANA 
No.     RO  Non-RO  subset  mRSS  mRSS  crisis   fibrosis 
1 F 67 47 51 Limited 4 4 No No Yes 74 Yes Ro60
2 F 53 53 53 Limited 10 10 No No Yes 64 Yes –
3 F 54 36 37 Diffuse 7 5 No No No 61 Yes –
4 F 66 57 59 Limited 5 5 No No No 90 Yes –
5 F 33 7 13 Diffuse 20 20 No No Yes 40 Yes Ro60, Ro52
6 F 73 15 69 Diffuse 22 22 No No Yes 37 Yes Ro52
7 M 30 25 26 Diffuse 18 18 No No No 94 Yes Ro52
8 F 43 34 35 Diffuse 30 14 No No Yes 115 Yes –
RO: Raynaud’s onset; max mRSS: maximal modified Rodnan skin score; last mRSS: modified Rodnan skin score at last follow-up; 
DU: digital ulcer; PH: pulmonary hypertension; DLCO: diffusion capacity of the lung for carbon monoxide (% of normal).
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between the onset of Raynaud’s phe-
nomenon and the first non-Raynaud’s 
feature of SSc was similar between all 
groups. None of the double-positive 
patients had left-ventricular heart fail-
ure, pulmonary hypertension (PH), 
proteinuria and none had experienced 
a renal crisis.
We also compared other clinical data of 
the double-positive SSc patients with 
those of patients that were documented 
as having either ACA or ATA alone (Ta-
ble II). As known from the clinical com-
parison between ACA and ATA single-
positives reported previously (11), the 
current study confirmed that the preva-
lence of a number of disease features 
differs between ATA single-positive and 
ACA single-positive SSc patients upon 
statistical testing. Most notably, muscu-
loskeletal, cardiopulmonary and cutane-
ous manifestations were more frequent 
in the ATA single-positives compared 
with the ACA-single positives.
Considering the ATA and ACA double-
positive cases, the prevalence of all 
organ manifestations was statistically 
similar to those in the ATA single-pos-
itives although there was a trend for 
more severe or prevalent involvement 
of the musculoskeletal system and of 
the pulmonary parenchyma in terms of 
lung fibrosis.
Taken together, the data confirm that 
positivity for either ATA or ACA is as-
sociated with significant differences 
in the prevalence of life-threatening 
organ complications of the pulmonary 
vasculature and parenchyma. Although 
patients with coexisting ATA and ACA 
tend to have more severe disease in 
some organ systems, the data do not 
demonstrate that double-positive pa-
tients are truly clinically different from 
ATA single-positive patients.
Discussion
We have evaluated the prevalence of co-
existing ATA and ACA in patients with 
SSc and found the simultaneous occur-
rence of ATA and ACA, two antibodies 
which are commonly regarded as mutu-
ally exclusive. In our rigorous analysis, 
the combined prevalence is low and 
perhaps even lower than that reported in 
smaller samples (14-16, 22). This study 
illustrates that the detection of ACA and 
ATA is not without problems. Due to 
the lack of a diagnostic gold standard, 
it is difficult to define when a specific 
test truly detects the antibody and clas-
sifies a sample as positive. First, tests 
may be false positive due to unspecific 
reactivity with non-target epitopes con-
taminating the antigen extract, as is 
documented in this study. Second, al-
though ANA immunofluorescence may 
be considered the standard method for 
ANA detection, it is however not specif-
ic because IIF patterns may be wrongly 
interpreted. Even the recognition of the 
ACA-associated pattern which is con-
sidered to be the most specific stain-
ing, is not without difficulty. As was 
shown in this study, one pattern may 
mask another pattern in the presence of 
two or more autoantibodies, especially 
when different titres are present. Third, 
the use of a cut-off value to discrimi-
nate between positive versus negative 
clearly represents an oversimplification. 
This is shown by the borderline positive 
case in this study. Recent studies have 
also recognised this problem and dem-
onstrated that the use of a scale of likeli-
hood ratios depending on the assay re-
sult renders an improved post-test prob-
ability (23). Another aspect of our work 
was that double-positive patients did 
have a high prevalence of Ro antibodies 
(anti-Ro52 and anti-Ro60) as described 
previously (24, 25), but did not harbour 
ARA as an SSc-specific antibody. This 
Table II. Prevalence of SSc manifestations according to autoantibody status. 
 Group 1 Group 2 Group 3 P P P
 ACA pos. ACA neg. ACA pos. Group 1 Group 1 Group 2
 ATA pos. ATA pos. ATA neg. vs. 2 vs. 3 vs. 3
Number of SSc patients 8 40 40   
dcSSc 62.5% 52.5% 2%  <0.001 <0.001
lcSSc 37.5% 45.0% 85.0%  <0.001 <0.001
Other (skin sclerosis distal of MCP/ MTP) 0% 2.5% 12.5%  0.01 <0.001
Age at last visit (mean years ± SD) 53.2 (15.2) 52.5 (14.8) 54.0 (14.0)   
Age at RO (mean years ± SD) 35.3 (15.2) 43.2 (14.6) 41.1 (16.0)   
Age at first non-Raynaud’s
(mean years ± SD) 43.1 (15.2) 44.6 (14.5) 48.3 (13.8)   
Time between RO and non-RO (median years (IQR)) 1 (0.5-4.6) 0.2 (0.5-2.5) 2.4 (0.1-7.9)   0.02*
Raynaud’s phenomenon 100% 97.5% 97.5%   
mRSS (mean ± SD) 12.4 (8.3) 9.3 (7.3) 3.1 (2.8)  <0.001 <0.001
Pulmonary fibrosis on x-ray 62.5% 57.5% 12.5%  0.01 <0.001
FVC (<80% predicted)  60.2% 40.0% 0%  <0.001 0.04
DLCO (% of predicted ± SD) 65.4 (20.1) 65.3 (22.4) 78.8 (20.0)  0.09 0.01
Joint contractures 57.1% 48.7% 17.5%  0.04 0.004
Synovitis 28.6% 12.5% 12.5%   
Tendon friction rubs 28.6% 23.1% 5.1%  0.04 0.04
Muscle weakness 71.4% 32.5% 27.5%  0.04 
Muscle atrophy 28.6% 15.0% 10.0%   
Creatine kinase elevation 14.2% 5.1% 5.0%   
Active disease 0% 0% 0%
ACA: anticentromere autoantibody; ATA: antitopoisomerase I autoantibody; mRSS: modified Rodnan skin score; DLCO: diffusion capac-
ity of the lung for carbon monoxide; FVC: forced vital capacity; RO: Raynaud’s onset; SD: standard deviation. Only p-values below 0.05 
are listed. *indicates the use of Wilcoxon’s test due to abnormal data distribution.   
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indicates that there is no promiscuity of 
the antibody response.
Importantly, our study is the first large 
multicentre prospective cohort study to 
systematically compare the clinical fea-
tures of patients with both antibodies to 
those harbouring either antibody alone, 
a method which is likely to reduce cen-
tre-related selection bias as a potential 
confounder (26). The main finding is 
that all clinical features of patients har-
bouring both serum autoantibodies are 
not statistically dissimilar from those 
harbouring solely ATA. Interestingly, 
none of the double-positive patients had 
PH. These observations however must 
be interpreted with caution due to the 
lack of statistical power. Furthermore, 
the differences between the single-
positive groups, although confirmed in 
larger cohorts (11), lack adjustment for 
multiple statistical testing and therefore 
should be regarded as descriptive.
The absence of a clear additive or 
synergistic effect of double antibody 
positivity on visceral involvement and 
disease evolution may be used as an ar-
gument against a direct involvement of 
ATA and ACA in the clinical phenotype 
of SSc. This notion is also supported by 
the lack of an association between the 
serum levels of SSc-specific antibodies 
and clinical activity, although limited 
data have suggested some association 
of ATA levels with the extent of or-
gan involvement and the difficult to 
measure disease activity (19, 27, 28). 
Our data therefore do not support se-
rial testing for these antibodies in ac-
cord with clinical practise (3). Other 
arguments against a direct pathogenic 
relevance of ACA and ATA in the SSc 
disease process are given by the fact 
that these antibodies may be detectable 
long term in healthy individuals with-
out subsequent disease development 
(3, 5, 22), and the observation that they 
can remain detectable after autologous 
stem cell transplantation despite com-
plete disease remission (29).
Finally, the finding of a low prevalence 
of double-positives which is lower than 
the expected probability of coincidence 
(13) does not support the postulate that 
environmental factors contribute to the 
ANAs in scleroderma. This notion is 
also suggested by the low prevalence of 
SSc-specific ANA in first degree rela-
tives and spouses of affected patients 
(30). In contrast to environmental fac-
tors, strong correlations with SSc-spe-
cific autoantibodies have recently been 
observed in multiple studies for certain 
HLA-class II alleles (31-33). Highly 
associated allelic combinations in the 
HLA-DQB1 locus have been dem-
onstrated with ACA and in the HLA-
DPA1/B1 loci with ATA (33), suggest-
ing that the alleles may drive different 
immunological processes involved in 
the production of these different au-
toantibodies. For this reason it would 
have been interesting to evaluate the 
HLA genotype of the ATA-ACA dou-
ble positive patients in our study, but 
genetic data were not collected in this 
EUSTAR project.
It should be noted that we have restrict-
ed our study to SSc patients diagnosed 
according to the ACR criteria and thus 
have excluded patients who have lim-
ited forms of SSc (34). This bias how-
ever is not likely to diminish the power 
by which clinical differences between 
double-positive and ATA single-positive 
patients may have been detected. Nev-
ertheless, our analysis is limited by the 
observational nature of the cohort, the 
large confidence intervals of the clini-
cal characteristics in the double-positive 
group due to the small number of pa-
tients.
In summary, our prospective analysis 
suggests a low prevalence of coexisting 
ATA and ACA in SSc after exclusion of 
false positives. The absence of a clearly 
discernible synergistic or additive ef-
fect of antibody status with respect to 
disease evolution, as well as cutaneous 
or visceral involvement does not sup-
port a direct pathogenic involvement 
of these antibodies in the established 
disease process, although such effect 
cannot be completely excluded due to 
limited statistical power.
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